Powered by MOMENTUM MEDIA
moneymanagement logo
 
 

SG Hiscock launches medical technology fund

sg-hiscock-&-company/SGH/stephen-hiscock/Hamish-Tadgell/medical/

29 June 2021
| By Chris Dastoor |
image
image image
expand image

SG Hiscock & Company (SGH) has launched a medical technology fund, investing in Australian medical technology companies.

The SGH Medical Technology fund would have a social impact focus and aimed to provide long-term capital growth by investing in a portfolio of medical technology companies where innovation played a crucial role in improving global health and economic outcomes.

The fund would invest in a mix of established and start-up medical technology companies, listed and unlisted, in Australia and New Zealand and hold 40 to 60 equities.

Rory Hunter, portfolio manager, said Australian medical technology was among the best in the world and the fund would offer investors access to high quality growth companies.

“Australia's history of medical breakthroughs includes penicillin, the bionic ear, ultrasounds, spray-on skin, and the cervical cancer vaccine,” Hunter said.

“In addition, there are many research facilities in Australia which are recognised as medical centres of excellence at a global level.

“Investors will also benefit from several tailwinds that are driving innovation and growth in medical research and technology.”

The fund would be run by the SGH emerging companies team and guided by the SGH medical technology advisory board, which was comprised of: 

  • Brenda Shanahan as chair (non-executive director, SGH; non-executive director, Clinuvel Pharmaceuticals; former chair, St Vincent’s Medical Research Institute; chair, Aitkenhead Centre for Medical Discovery);
  • Professor Mark Cook (chair of medicine, St Vincent’s Hospital; chair of medicine, University of Melbourne; state chair, Victoria, Australian and New Zealand Association of Neurologists; director, Graeme Clarke Institute for Biomedical Engineering);
  • Sam Lanyon (co-CEO and co-founder, Planet Innovation; executive chair, Lumos Diagnostics);
  • Stephen Hiscock (chair and managing director, SGH; director, DMP Asset Management); and
  • Hamish Tadgell (head of research, SGH; portfolio manager, SGH20).

SGH would also establish a registered charitable foundation which will be funded by 10% of net revenue from the SGH Medical Technology fund, including performance fees.

Read more about:

AUTHOR

Recommended for you

sub-bgsidebar subscription

Never miss the latest news and developments in wealth management industry

MARKET INSIGHTS

Significant ethical issues there. If a relationship is in the process of breaking down then both parties are likely to b...

1 week 3 days ago

It's not licensees not putting them on, it's small businesses (that are licensed) that cannot afford to put them on. The...

2 weeks 3 days ago

So we are now underwriting criminal scams?...

6 months 3 weeks ago

After last month’s surprise hold, the Reserve Bank of Australia has announced its latest interest rate decision....

1 week 4 days ago

A professional year supervisor has been banned for five years after advice provided by his provisional relevant provider was deemed to be inappropriate, the first time th...

3 weeks 3 days ago

WT Financial’s Keith Cullen is eager for its Hubco initiative to see advice firms under its licence trade at multiples which are catching up to those UK and US financial ...

2 weeks 1 day ago

TOP PERFORMING FUNDS

ACS FIXED INT - AUSTRALIA/GLOBAL BOND
Fund name
3y(%)pa
1
DomaCom DFS Mortgage
74.26 3 y p.a(%)
3